Translational Medicine in Acute Ischemic Stroke and Traumatic Brain Injury—NeuroAiD Trials, from Traditional Beliefs to Evidence-Based Therapy
Biomolecules · 2024
DOI: 10.3390/biom14060680 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2024. Verfasst von Narayanaswamy Venketasubramanian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Raffles Neuroscience Centre, Raffles Hospital, 585 North Bridge Road, Singapore 188770, Singapore. Hauptthemen laut MEDLINE: Brain Injuries, Traumatic, Ischemic Stroke, Drugs, Chinese Herbal, Translational Research, Biomedical. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Acute ischemic stroke (AIS) and traumatic brain injury (TBI) are two severe neurological events, both being major causes of death and prolonged impairment. Their incidence continues to rise due to the global increase in the number of people at risk, representing a significant burden on those remaining impaired, their families, and society. These molecular and cellular mechanisms of both stroke and TBI present similarities that can be targeted by treatments with a multimodal mode of action, such as traditional Chinese medicine. Therefore, we performed a detailed review of the preclinical and clinical development of MLC901 (NeuroAiDTMII), a natural multi-herbal formulation targeting several biological pathways at the origin of the clinical deficits. The endogenous neurobiological processes of self-repair initiated by the brain in response to the onset of brain injury are often insufficient to achieve complete recovery of impaired functions. This review of MLC901 and its parent formulation MLC601 confirms that it amplifies the natural self-repair process of brain tissue after AIS or TBI. Following AIS and TBI where "time is brain", many patients enter the post-acute phase with their functions still impaired, a period when "the brain needs time to repair itself". The treatment goal must be to accelerate recovery as much as possible. MLC901/601 demonstrated a significant reduction by 18 months of recovery time compared to a placebo, indicating strong potential for facilitating the improvement of health outcomes and the more efficient use of healthcare resources.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Raffles Neuroscience Centre, Raffles Hospital, 585 North Bridge Road, Singapore 188770, Singapore.
- Division of Neurosurgery, Department of Surgery, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074, Singapore.
- Memory Aging and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Blk MD3, 16 Medical Drive, #04-01, Singapore 117600, Singapore.
ORCID-Profile: Narayanaswamy Venketasubramanian, Christopher Li Hsian Chen
Zitieren
APA
Venketasubramanian, N., Yeo, T. T., & Chen, C. L. H. (2024). Translational Medicine in Acute Ischemic Stroke and Traumatic Brain Injury—NeuroAiD Trials, from Traditional Beliefs to Evidence-Based Therapy. Biomolecules. https://doi.org/10.3390/biom14060680
Vancouver
Venketasubramanian N, Yeo TT, Chen CLH. Translational Medicine in Acute Ischemic Stroke and Traumatic Brain Injury—NeuroAiD Trials, from Traditional Beliefs to Evidence-Based Therapy. Biomolecules. 2024. doi:10.3390/biom14060680
BibTeX
@article{Venketasubramanian2024,
author = {Venketasubramanian, Narayanaswamy and Yeo, Tseng Tsai and Chen, Christopher Li Hsian},
title = {Translational Medicine in Acute Ischemic Stroke and Traumatic Brain Injury—NeuroAiD Trials, from Traditional Beliefs to Evidence-Based Therapy},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14060680}
}
EUVIMED